Patterns of Recurrence After Surgery for Pancreatic Cancer

[1]  S. Ahrendt,et al.  Prognosis Based Definition of Resectability in Pancreatic Cancer , 2020, Annals of surgery.

[2]  A. Zwinderman,et al.  Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Jin-Young Jang,et al.  International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[4]  J. Cameron,et al.  Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer. , 2019, Annals of surgery.

[5]  M. Büchler,et al.  Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. , 2019, JAMA surgery.

[6]  M. Büchler,et al.  Meta‐analysis of recurrence pattern after resection for pancreatic cancer , 2019, The British journal of surgery.

[7]  J. Nuyttens,et al.  Postoperative surveillance of pancreatic cancer patients. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[8]  J. Cameron,et al.  Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  J. Cameron,et al.  Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival. , 2019, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[10]  J. Cameron,et al.  Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. , 2019, Annals of surgery.

[11]  T. Hackert,et al.  The Time to and Type of Pancreatic Cancer Recurrence after Surgical Resection: Is Prediction Possible? , 2019, Academic radiology.

[12]  Song-Cheol Kim,et al.  Management of isolated recurrence after surgery for pancreatic adenocarcinoma , 2019, The British journal of surgery.

[13]  Roberto J. Rivero-Soto,et al.  Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. , 2019, Annals of surgery.

[14]  Lisa M Haley,et al.  Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer , 2019, Clinical Cancer Research.

[15]  E. Steyerberg,et al.  Systematic review of clinical prediction models for survival after surgery for resectable pancreatic cancer , 2019, The British journal of surgery.

[16]  A. Maitra,et al.  Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. , 2019, Gastroenterology.

[17]  Thierry Lecomte,et al.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer , 2018, The New England journal of medicine.

[18]  Bas Groot Koerkamp,et al.  International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer , 2018, JAMA surgery.

[19]  elliot k fishman,et al.  ASO Author Reflections: Do Distinct Patterns of Recurrence Impact the Prognosis of Patients With Resected Pancreatic Ductal Adenocarcinoma? , 2018, Annals of Surgical Oncology.

[20]  M. Makary,et al.  Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate With Disease Status: Results of the Prospective CLUSTER Study , 2018, Annals of surgery.

[21]  S. Choi,et al.  Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial , 2018, Annals of surgery.

[22]  M. Makary,et al.  Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer? , 2018, Annals of surgery.

[23]  J. Cameron,et al.  Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma , 2018, Annals of Surgical Oncology.

[24]  H. Heerkens,et al.  Systematic review on the role of serum tumor markers in the detection of recurrent pancreatic cancer. , 2018, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[25]  H. Friess,et al.  Meta‐analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma , 2018, BJS open.

[26]  Brooke L. Billman,et al.  Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Ohtsuka,et al.  Primary Recurrence in the Lung is Related to Favorable Prognosis in Patients with Pancreatic Cancer and Postoperative Recurrence , 2017, World Journal of Surgery.

[28]  I. B. Borel Rinkes,et al.  Current Strategies for Detection and Treatment of Recurrence of Pancreatic Ductal Adenocarcinoma After Resection: A Nationwide Survey , 2017, Pancreas.

[29]  B. Melichar,et al.  Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature , 2017, World journal of gastroenterology.

[30]  M. House,et al.  Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma , 2017, American journal of clinical oncology.

[31]  L. Schwartz,et al.  Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas , 2017, BMC Cancer.

[32]  J. Cameron,et al.  Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma , 2017, Annals of surgery.

[33]  I. B. Borel Rinkes,et al.  Systematic review on the treatment of isolated local recurrence of pancreatic cancer after surgery; re-resection, chemoradiotherapy and SBRT. , 2017, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[34]  K. Hirakawa,et al.  Preoperative predictors for early recurrence of resectable pancreatic cancer , 2017, World Journal of Surgical Oncology.

[35]  E. Hiyama,et al.  Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer , 2016, British Journal of Cancer.

[36]  A. Parikh,et al.  Adjuvant Therapy in Pancreas Cancer: Does It Influence Patterns of Recurrence? , 2016, Journal of the American College of Surgeons.

[37]  E. Fishman,et al.  Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns , 2015, Oncotarget.

[38]  B. Nardo,et al.  Metastases of pancreatic adenocarcinoma: A systematic review of literature and a new functional concept. , 2015, International journal of surgery.

[39]  M. McCarter,et al.  Characteristics of 10-Year Survivors of Pancreatic Ductal Adenocarcinoma. , 2015, JAMA surgery.

[40]  C. Sakakura,et al.  Optimal duration of the early and late recurrence of pancreatic cancer after pancreatectomy based on the difference in the prognosis. , 2014, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[41]  M. Kanda,et al.  Pattern of first recurrent lesions in pancreatic cancer: hepatic relapse is associated with dismal prognosis and portal vein invasion. , 2014, Hepato-gastroenterology.

[42]  M. Makary,et al.  The Impact of Postoperative Complications on the Administration of Adjuvant Therapy Following Pancreaticoduodenectomy for Adenocarcinoma , 2014, Annals of Surgical Oncology.

[43]  A. Moser,et al.  Resection of isolated local and metastatic recurrence in periampullary adenocarcinoma. , 2014, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[44]  H. Kanemoto,et al.  Margin status, recurrence pattern, and prognosis after resection of pancreatic cancer. , 2013, Surgery.

[45]  E. Fishman,et al.  Recent progress in pancreatic cancer , 2013, CA: a cancer journal for clinicians.

[46]  M A Firpo,et al.  The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. , 2013, Current molecular medicine.

[47]  H. Furukawa,et al.  Serum CA19-9 is a Significant Predictor among Preoperative Parameters for Early Recurrence after Resection of Pancreatic Adenocarcinoma , 2012, Journal of Gastrointestinal Surgery.

[48]  N. Habib,et al.  Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy , 2012, Journal of Cancer Research and Clinical Oncology.

[49]  Tae Hyun Kim,et al.  CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer. , 2011, International journal of radiation oncology, biology, physics.

[50]  A. Zalatnai,et al.  Pancreatic Carcinomas in a 60-Year, Institute-Based Autopsy Material With Special Emphasis of Metastatic Pattern , 2011, Pancreas.

[51]  S. Seno,et al.  Gene Expression Profile Prospectively Predicts Peritoneal Relapse After Curative Surgery of Gastric Cancer , 2010, Annals of Surgical Oncology.

[52]  B. Topal,et al.  Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[53]  Alison P. Klein,et al.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  M. Choti,et al.  Determining Pattern of Recurrence Following Pancreaticoduodenectomy and Adjuvant 5-Flurouracil-Based Chemoradiation Therapy: Effect of Number of Metastatic Lymph Nodes and Lymph Node Ratio , 2009, Journal of Gastrointestinal Surgery.

[55]  H. Yamaue,et al.  Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma , 2009, Langenbeck's Archives of Surgery.

[56]  Y. Ogata,et al.  Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings , 2006, Journal of Gastrointestinal Surgery.

[57]  S. Kitano,et al.  Factors Predicting Recurrence After Resection of Pancreatic Ductal Carcinoma , 2005, Pancreas.

[58]  S. Gallinger,et al.  Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. , 2004, Journal of the American College of Surgeons.

[59]  D. Gouma,et al.  Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. , 2004, European journal of cancer.

[60]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Olivier Cussenot,et al.  Gene expression profiling in clinically localized prostate cancer: a four-gene expression model predicts clinical behavior. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  C. Earle,et al.  Prognostic Factors Following Curative Resection for Pancreatic Adenocarcinoma: A Population-Based, Linked Database Analysis of 396 Patients , 2003, Annals of surgery.

[63]  K. Lillemoe,et al.  Resected adenocarcinoma of the pancreas— 616 patients: Results, outcomes, and prognostic indicators , 2000, Journal of Gastrointestinal Surgery.

[64]  A. Piccoli,et al.  Recurrence after resection for ductal adenocarcinoma of the pancreas , 1997, World Journal of Surgery.

[65]  M. Koike,et al.  Hematogenous Metastases of Pancreatic Ductal Carcinoma , 1995, Pancreas.

[66]  P. Johnstone,et al.  Patterns of disease recurrence following definitive therapy of adenocarcinoma of the pancreas using surgery and adjuvant radiotherapy:correlations of a clinical trial. , 1993, International journal of radiation oncology, biology, physics.

[67]  Toshiya Takeda,et al.  An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging , 1993, Cancer.

[68]  Y. Morioka,et al.  Lymphatic and Local Spread of T1 and T2 Pancreatic Cancer: A Study of Autopsy Material , 1986, Annals of surgery.

[69]  J. Fortner.  Regional Pancreatectomy for Cancer of the Pancreas, Ampulla, and Other Related Sites: Tumor Staging and Results , 1984, Annals of surgery.

[70]  M. B. Rosenblatt,et al.  Pulmonary manifestations of carcinoma of the pancreas , 1964, Cancer.

[71]  I. B. Borel Rinkes,et al.  Use of imaging during symptomatic follow-up after resection of pancreatic ductal adenocarcinoma. , 2018, The Journal of surgical research.

[72]  T. Pawlik,et al.  Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective , 2017, Annals of Surgical Oncology.

[73]  N. Pavlakis,et al.  Patterns and Determinants of Recurrence for Pancreatic Ductal Adenocarcinoma after Resection , 2017 .

[74]  Steven J. Cohen,et al.  Impact of preoperative therapy on patterns of recurrence in pancreatic cancer. , 2014, HPB : the official journal of the International Hepato Pancreato Biliary Association.